ABSTRACT
Science commercialization directly applies the latest findings from scientific research into new products and services that are then advertised and sold in a capitalist market economy. This chapter explores the case of Treximet to illustrate how information is communicated to health care professionals and scientists in the context of pharmaceutical commercialization, a prominent form of neoliberal science commercialization. The information revealed to these experts is not only selective but distorted to broaden the commercial market for a specific therapeutic drug treatment. This case study shows that information sharing in science commercialization is in direct contrast to the ethical foundations of information sharing in science and, moreover, echoes the ethical concern that the commercializing of scientific advancements, particularly by the pharmaceutical industry, is motivated by the desire for excessive profit through exploitative commodification rather than authentic human good. The scientific publishing process attempts to regulate ethical practice by limiting one's ability to publish research and thus reap the benefit of publication.
